Novartis Ag Patent Portfolio Statistics

tip_user1

Novartis Ag

Profile Summary

This article summarizes the perfomance of the assignee in the recent years. The overall statistics for this portfolio help to analyze the areas where the assignee is performing well. The filing trend, perfomance across the tech centers and the perfomance of the recent applications has been mentioned below. All the stats are calculated based on the perfomance in USPTO.

How does the overall patent portfolio of Novartis Ag look like?

Assignee Art Units
Total Applications: 7,191 2,117,369
Granted Patents: 4,879 1,165,335
Grant Index 73.87% ↑ 68.44%
Abandoned/Rejected Applications: 1,726 (26.13%) 537,449 (31.56%)
In-Process Applications: 583 414,585
Average Grant Time: 2.92 Years ↑ 2.8 Years
Average Office Actions: 1.77 ↑ 1.71

Which Technology Area Novartis Ag is filing most patents in? (Last 10 years)

Art Unit Definition Total Applications
1624 Organic Chemistry 459
1626 Organic Chemistry 425
1625 Organic Chemistry 302
1645 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology 288
1628 Organic Chemistry 215

How many patents are Novartis Ag filing every year?

Year Total Applications Predicted
2022 0* 735
2021 119* 663
2020 204 584
2019 258 258
2018 371 –
2017 310 –
2016 346 –
2015 383 –
2014 441 –
2013 399 –

*The drop in the number of applications filed in last two years compared to previous years is because applications can take up to 18 months to get published

Recently filed patent applications of Novartis Ag in USPTO?

Publication number: None
Application number: 17/569,389

Abstract:
–

Publication date: –
Applicant: Novartis Ag
Inventors: Brogdon Jennifer

Publication number: US20220180319A1
Application number: 17/541,441

Abstract:
A platform and method for enabling collaboration on data analysis of life sciences data across disparate databases are disclosed. The collaboration platform may allow for performing exploratory analysis for drug discovery and development. The collaboration platform may include a search and graph module for generating a user project and determining and displaying one or more matching data assets and one or more potential collaborators; a collaboration module for coordinating a collaboration between the user and one or more selected collaborators; a data management module for receiving a schema for one or more producer projects, receiving data from the one or more selected data assets, and ingesting the received data using common standards and an ontology; and an insight application for generating disease specific inferences relating to a scientific question using the ingested received data, and receiving a feedback from the user and/or the selected collaborators to improve the search and graph module.

Publication date: 2022-06-09
Applicant: Novartis Ag
Inventors: Badhri Srinivasan

Publication number: US20220073537A1
Application number: 17/532,367

Abstract:
The present invention relates to compounds of formula I:in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Publication date: 2022-03-10
Applicant: Novartis Ag
Inventors: Blas Lawrence Perez

How are Novartis Ag’s applications performing in USPTO?

Application Number Title Status Art Unit Examiner
17/569,389 Nucleic Acid Molecules Encoding Chimeric Antigen Receptors Comprising A Cd20 Binding Domain Docketed New Case – Ready for Examination 3991 Witz, Jean C
17/541,441 Collaboration Platform For Enabling Collaboration On Data Analysis Across Multiple Disparate Databases – 1631 Frumkin, Jesse P
17/532,367 N-Azaspirocycloalkane Substituted N-Heteroaryl Compounds And Compositions For Inhibiting The Activity Of Shp2 Docketed New Case – Ready for Examination OPAP Central, Docket